William Blair Predicts Envista’s Q4 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Research analysts at William Blair lifted their Q4 2025 EPS estimates for shares of Envista in a note issued to investors on Thursday, February 6th. William Blair analyst B. Vazquez now anticipates that the company will earn $0.34 per share for the quarter, up from their previous forecast of $0.33. The consensus estimate for Envista’s current full-year earnings is $0.72 per share. William Blair also issued estimates for Envista’s Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.24 EPS and Q3 2026 earnings at $0.23 EPS.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%.

Other research analysts also recently issued reports about the stock. Piper Sandler boosted their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Wells Fargo & Company upped their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday. Mizuho assumed coverage on Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Finally, Robert W. Baird upped their price target on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Envista has an average rating of “Hold” and an average target price of $20.21.

Envista Price Performance

Shares of NVST stock opened at $21.76 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. The firm has a market cap of $3.75 billion, a P/E ratio of -2.80, a P/E/G ratio of 1.82 and a beta of 1.34. The business’s 50 day moving average price is $19.96 and its 200-day moving average price is $19.12. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $24.79.

Institutional Investors Weigh In On Envista

A number of institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Envista during the fourth quarter valued at $10,808,000. Proficio Capital Partners LLC bought a new position in shares of Envista during the 4th quarter valued at about $358,000. M&T Bank Corp grew its position in shares of Envista by 4.2% during the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock valued at $320,000 after purchasing an additional 676 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Envista by 2.5% in the fourth quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after purchasing an additional 983 shares during the last quarter. Finally, Keybank National Association OH purchased a new stake in shares of Envista in the fourth quarter worth about $234,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.